Evidence map›Paper›PMID 33842909›Full record

ArticleIBRO neuroscience reports2021

Intracisternal administration of tanshinone IIA-loaded nanoparticles leads to reduced tissue injury and functional deficits in a porcine model of ischemic stroke.

Elizabeth S Waters, Erin E Kaiser, Xueyuan Yang, Madison M Fagan, Kelly M Scheulin, Julie H Jeon, Soo K Shin, Holly A Kinder, Anil Kumar, Simon R Platt and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IBRO neuroscience reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Elizabeth S WatersRegenerative Bioscience Center, University of Georgia, Athens, GA 30602, United States.
Erin E KaiserRegenerative Bioscience Center, University of Georgia, Athens, GA 30602, United States.
Xueyuan YangDepartment of Chemistry, Franklin College of Arts and Sciences, University of Georgia, Athens, GA 30602, United States.
Madison M FaganRegenerative Bioscience Center, University of Georgia, Athens, GA 30602, United States.
Kelly M ScheulinRegenerative Bioscience Center, University of Georgia, Athens, GA 30602, United States.
Julie H JeonDepartment of Foods and Nutrition, College of Family and Consumer Sciences, University of Georgia, Athens, GA 30602, United States.
Soo K ShinRegenerative Bioscience Center, University of Georgia, Athens, GA 30602, United States.
Holly A KinderRegenerative Bioscience Center, University of Georgia, Athens, GA 30602, United States.
Anil KumarDepartment of Chemistry, Franklin College of Arts and Sciences, University of Georgia, Athens, GA 30602, United States.
Simon R PlattRegenerative Bioscience Center, University of Georgia, Athens, GA 30602, United States.
Kylee J DubersteinRegenerative Bioscience Center, University of Georgia, Athens, GA 30602, United States.
Hea Jin ParkDepartment of Foods and Nutrition, College of Family and Consumer Sciences, University of Georgia, Athens, GA 30602, United States.
Jin XieRegenerative Bioscience Center, University of Georgia, Athens, GA 30602, United States.
Franklin D WestRegenerative Bioscience Center, University of Georgia, Athens, GA 30602, United States.
University of Georgia · USFranklin College · US

Funding

Combined Nanoparticle and Neural Stem Cell Therapies in a Pig Model of StrokeR01NS093314 · NINDS · UNIVERSITY OF GEORGIA · PI WEST, FRANKLIN D · 2015 to 2019
$2.4M
Nanoscintillator-based X-ray sensitizers to enable efficient NSCLC treatment with X-ray irradiationR01EB022596 · NIBIB · UNIVERSITY OF GEORGIA · PI XIE, JIN · 2017 to 2020
$1.9M
NIBIB NIH HHS R01 EB022596NINDS NIH HHS R01 NS093314
6 · The paper itself

Abstract

backgroundThe absolute number of new stroke patients is annually increasing and there still remains only a few Food and Drug Administration (FDA) approved treatments with significant limitations available to patients. Tanshinone IIA (Tan IIA) is a promising potential therapeutic for ischemic stroke that has shown success in pre-clinical rodent studies but lead to inconsistent efficacy results in human patients. The physical properties of Tan-IIA, including short half-life and low solubility, suggests that Poly (lactic-co-glycolic acid) (PLGA) nanoparticle-assisted delivery may lead to improve bioavailability and therapeutic efficacy. The objective of this study was to develop Tan IIA-loaded nanoparticles (Tan IIA-NPs) and to evaluate their therapeutic effects on cerebral pathological changes and consequent motor function deficits in a pig ischemic stroke model.

resultsTan IIA-NP treated neural stem cells showed a reduction in SOD activity in in vitro assays demonstrating antioxidative effects. Ischemic stroke pigs treated with Tan IIA-NPs showed reduced hemispheric swelling when compared to vehicle only treated pigs (7.85 ± 1.41 vs. 16.83 ± 0.62%), consequent midline shift (MLS) (1.72 ± 0.07 vs. 2.91 ± 0.36 mm), and ischemic lesion volumes (9.54 ± 5.06 vs. 12.01 ± 0.17 cm

conclusionThe findings of this proof of concept study strongly suggest that administration of Tan IIA-NPs in the acute phase post-stroke mitigates neural injury likely through limiting free radical formation, thus leading to less severe gait deficits in a translational pig ischemic stroke model. With stroke as one of the leading causes of functional disability in the United States, and gait deficits being a major component, these promising results suggest that acute Tan IIA-NP administration may improve functional outcomes and the quality of life of many future stroke patients.

Indexed as

ADC, Apparent Diffusion CoefficientANOVA, analysis of varianceAU, arbitrary unitsBaic, BaicalinBBB, blood brain barrierCNS, central nervous systemCSF, cerebral spinal fluidDAMPS, damaged-associated molecular patternsddH2O, double-distilled waterDLS, dynamic light scatteringDTI, Diffusion Tensor ImagingDWI, Diffusion-Weighted ImagingEdar, EdaravoneFA, fractional anisotropyFDA, Food and Drug AdministrationGABA, γ-aminobutyric acidGM, gray matterICH, intracerebral hemorrhageIC, inhibitory concentrationIL-6, interleukin 6IM, intramuscularIschemic strokeLPS, lipopolysaccharideMCA, middle cerebral arteryMCAO, middle cerebral artery occlusionMLS, midline shiftNanomedicineNP, nanoparticleNSCs, neural stem cellsPBS, phosphate buffered salinePEG–PLGA, polyethyleneglycol–polylactic-co-glycolic acidPig stroke modelPiog, PioglitazonePLGA-b-PEG-OH, poly (lactide-co-glycolide)-b-poly (ethylene glycol)-maleimidePLGA nanoparticlePLGA, Poly (lactic-co-glycolic acid)Puer, PuerarinResv, ResveratrolROS, reactive oxygen speciesSOD, superoxide dismutaseSTAIR, Stroke Therapy Academic and Industry RoundtableT2FLAIR, T2 Fluid Attenuated Inversion RecoveryT2*, T2StarT2W, T2WeightedTan IIA-NPs, Tan IIA-loaded nanoparticlesTan IIA-NPs, Tan IIA PLGA NPsTan IIA, Tanshinone IIATanshinone IIATD, transdermalTEM, transmission electron microscopyTNF-α, tumor necrosis factor αtPA, Tissue plasminogen activatorUGA, University of GeorgiaWM, white matter

Identifiers

PMID33842909
PMCPMC8019951
OpenAlexW3126997484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.